These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 7593434)

  • 1. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis.
    Kimonis VE; Troendle J; Rose SR; Yang ML; Markello TC; Gahl WA
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3257-61. PubMed ID: 7593434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with recombinant human growth hormone in short children with nephropathic cystinosis: no evidence for increased deterioration rate of renal function. The European Study Group on Growth Hormone Treatment in Short Children with Nephropathic Cystinosis.
    Wühl E; Haffner D; Gretz N; Offner G; van't Hoff WG; Broyer M; Mehls O
    Pediatr Res; 1998 Apr; 43(4 Pt 1):484-8. PubMed ID: 9545002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy.
    Tsilou ET; Rubin BI; Reed G; Caruso RC; Iwata F; Balog J; Gahl WA; Kaiser-Kupfer MI
    Ophthalmology; 2006 Jun; 113(6):1002-9. PubMed ID: 16603246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteamine therapy for children with nephropathic cystinosis.
    Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA
    N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy.
    Sonies BC; Almajid P; Kleta R; Bernardini I; Gahl WA
    Medicine (Baltimore); 2005 May; 84(3):137-146. PubMed ID: 15879904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.
    Bendel-Stenzel MR; Steinke J; Dohil R; Kim Y
    Pediatr Nephrol; 2008 Feb; 23(2):311-5. PubMed ID: 17668247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved renal function in children with cystinosis treated with cysteamine.
    Markello TC; Bernardini IM; Gahl WA
    N Engl J Med; 1993 Apr; 328(16):1157-62. PubMed ID: 8455682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early oral cysteamine therapy for nephropathic cystinosis.
    Gahl WA
    Eur J Pediatr; 2003 Dec; 162 Suppl 1():S38-41. PubMed ID: 14610675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
    Gahl WA; Balog JZ; Kleta R
    Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of cystinosis using cysteamine].
    Broyer M; Tete MJ
    Ann Pediatr (Paris); 1990 Feb; 37(2):91-3. PubMed ID: 2321906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Swallowing dysfunction in nephropathic cystinosis.
    Sonies BC; Ekman EF; Andersson HC; Adamson MD; Kaler SG; Markello TC; Gahl WA
    N Engl J Med; 1990 Aug; 323(9):565-70. PubMed ID: 2381441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cysteamine in the treatment of cystinosis in children. In vitro and in vivo studies].
    Louis JJ; Guibaud P; Dumoulin R; Parchoux B; Zabot MT; Bureau J; Baltassat P; Frederich A; Larbre F
    Pediatrie; 1984 Dec; 39(8):619-33. PubMed ID: 6535971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management dilemmas in pediatric nephrology: Cystinosis.
    Besouw MT; Van Dyck M; Cassiman D; Claes KJ; Levtchenko EN
    Pediatr Nephrol; 2015 Aug; 30(8):1349-60. PubMed ID: 25956701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.
    Smolin LA; Clark KF; Thoene JG; Gahl WA; Schneider JA
    Pediatr Res; 1988 Jun; 23(6):616-20. PubMed ID: 3393396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.